In vitro aldose reductase inhibitory activity of some flavonyl-2,4-thiazolidinediones. 2008

Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
Department of Biochemistry, Faculty of Pharmacy, Ankara University. evcimen@pharmacy.ankara.edu.tr

Aldose reductase (AR) is implicated to play a critical role in diabetes and cardiovascular complications because of the reaction it catalyzes. AR enzyme appears to be the key factor in the reduction of glucose to sorbitol. Synthesis and accumulation of sorbitol in cells due to AR activity is the main cause of diabetic complications, such as diabetic cataract, retinopathy, neuropathy and nephropathy. Aldose reductase inhibitors have been found to prevent sorbitol accumulation in tissues. Numerous compounds have been prepared in order to improve the pharmacological prophile of inhibition of aldose reductase enzyme. In this study, seventeen flavonyl-2,4-thiazolidinediones (flavonyl-2,4-TZD) (Ia-e, IIa-e and IIIa-g) were tested for their ability to inhibit rat kidney AR. Compound Ib showed the highest inhibitory activity (88.69 +/- 1.46%) whereas Ia, IIa, IIIa, IIIb also showed significant inhibitory activity (49.26 +/- 2.85, 67.29 +/- 1.09, 71.11 +/- 1.95, 64.86 +/- 1.21%, respectively).

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000449 Aldehyde Reductase An enzyme that catalyzes reversibly the oxidation of an aldose to an alditol. It possesses broad specificity for many aldoses. EC 1.1.1.21. Aldose Reductase,Aldose Reductase Ia,Aldose Reductase Ib,Erythrose Reductase,Xylose Reductase,Reductase Ia, Aldose,Reductase Ib, Aldose,Reductase, Aldehyde,Reductase, Aldose,Reductase, Erythrose,Reductase, Xylose
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D045162 Thiazolidinediones THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). Glitazones
D047309 Flavones A group of 4-keto-FLAVONOIDS. 2-Phenyl-2-Ene-Benzopyran-4-One Compounds
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
January 2006, Bioorganic & medicinal chemistry,
Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
April 2002, Bioorganic & medicinal chemistry,
Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
July 2007, Bioorganic & medicinal chemistry letters,
Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
January 2003, Farmaco (Societa chimica italiana : 1989),
Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
January 2001, Arzneimittel-Forschung,
Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
June 2000, Arzneimittel-Forschung,
Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
July 2000, Arzneimittel-Forschung,
Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
February 2006, Bioorganic & medicinal chemistry letters,
Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
July 2009, Journal of molecular modeling,
Net Daş-Evcimen, and Oya Bozdağ-Dündar, and Mutlu Sarikaya, and Rahmiye Ertan
April 2005, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!